144 related articles for article (PubMed ID: 30094617)
21. Biomarkers for the early detection of relapses in metastatic colorectal cancers.
Chereches G; Barbos O; Buiga R; Balacescu O; Iancu D; Todor N; Balacescu L; Miron N; Bejinariu N; Ciuleanu TE
J BUON; 2017; 22(3):658-666. PubMed ID: 28730771
[TBL] [Abstract][Full Text] [Related]
22. Prognostic value of CD133
Fang C; Fan C; Wang C; Huang Q; Meng W; Yu Y; Yang L; Hu J; Li Y; Mo X; Zhou Z
Cancer Med; 2017 Dec; 6(12):2850-2857. PubMed ID: 29105339
[TBL] [Abstract][Full Text] [Related]
23. KRAS mutation analysis of single circulating tumor cells from patients with metastatic colorectal cancer.
Kondo Y; Hayashi K; Kawakami K; Miwa Y; Hayashi H; Yamamoto M
BMC Cancer; 2017 May; 17(1):311. PubMed ID: 28468669
[TBL] [Abstract][Full Text] [Related]
24. RAC1b overexpression correlates with poor prognosis in KRAS/BRAF WT metastatic colorectal cancer patients treated with first-line FOLFOX/XELOX chemotherapy.
Alonso-Espinaco V; Cuatrecasas M; Alonso V; Escudero P; Marmol M; Horndler C; Ortego J; Gallego R; Codony-Servat J; Garcia-Albeniz X; Jares P; Castells A; Lozano JJ; Rosell R; Maurel J
Eur J Cancer; 2014 Jul; 50(11):1973-81. PubMed ID: 24833563
[TBL] [Abstract][Full Text] [Related]
25. PD-L1 Expression on Circulating Tumour Cells May Be Predictive of Response to Regorafenib in Patients Diagnosed with Chemorefractory Metastatic Colorectal Cancer.
Raimondi L; Raimondi FM; Di Benedetto L; Cimino G; Spinelli GP
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32962309
[TBL] [Abstract][Full Text] [Related]
26. Molecular detection of circulating tumor cells in the peripheral blood of patients with colorectal cancer using RT-PCR: significance of the prediction of postoperative metastasis.
Wang JY; Wu CH; Lu CY; Hsieh JS; Wu DC; Huang SY; Lin SR
World J Surg; 2006 Jun; 30(6):1007-13. PubMed ID: 16736329
[TBL] [Abstract][Full Text] [Related]
27. Detection of circulating tumor cells in peripheral blood of colorectal cancer patients without distant organ metastases.
Liu Y; Qian J; Feng JG; Ju HX; Zhu YP; Feng HY; Li DC
Cell Oncol (Dordr); 2013 Feb; 36(1):43-53. PubMed ID: 23150200
[TBL] [Abstract][Full Text] [Related]
28. RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients.
Yao J; Zang W; Ge Y; Weygant N; Yu P; Li L; Rao G; Jiang Z; Yan R; He L; Yu Y; Jin M; Cheng G; An G
Can J Gastroenterol Hepatol; 2018; 2018():4248971. PubMed ID: 29707525
[TBL] [Abstract][Full Text] [Related]
29. Circulating tumor cells in metastatic colorectal cancer: do we need an alternative cutoff?
Gazzaniga P; Raimondi C; Gradilone A; Biondi Zoccai G; Nicolazzo C; Gandini O; Longo F; Tomao S; Lo Russo G; Seminara P; Vincenzi B; Chimenti I; Cristofanilli M; Frati L; Cortesi E
J Cancer Res Clin Oncol; 2013 Aug; 139(8):1411-6. PubMed ID: 23736274
[TBL] [Abstract][Full Text] [Related]
30. KRAS mutations in tumor tissue and plasma by different assays predict survival of patients with metastatic colorectal cancer.
Xu JM; Liu XJ; Ge FJ; Lin L; Wang Y; Sharma MR; Liu ZY; Tommasi S; Paradiso A
J Exp Clin Cancer Res; 2014 Dec; 33(1):104. PubMed ID: 25491325
[TBL] [Abstract][Full Text] [Related]
31. Clinicopathologic features and treatment efficacy of Chinese patients with BRAF-mutated metastatic colorectal cancer: a retrospective observational study.
Wang X; Wei Q; Gao J; Li J; Li J; Gong J; Li Y; Shen L
Chin J Cancer; 2017 Oct; 36(1):81. PubMed ID: 29037218
[TBL] [Abstract][Full Text] [Related]
32. Quantitative real-time RT-PCR detection for survivin, CK20 and CEA in peripheral blood of colorectal cancer patients.
Shen C; Hu L; Xia L; Li Y
Jpn J Clin Oncol; 2008 Nov; 38(11):770-6. PubMed ID: 18845519
[TBL] [Abstract][Full Text] [Related]
33. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
Douillard JY; Siena S; Cassidy J; Tabernero J; Burkes R; Barugel M; Humblet Y; Bodoky G; Cunningham D; Jassem J; Rivera F; Kocákova I; Ruff P; Błasińska-Morawiec M; Šmakal M; Canon JL; Rother M; Oliner KS; Wolf M; Gansert J
J Clin Oncol; 2010 Nov; 28(31):4697-705. PubMed ID: 20921465
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of the Role of Circulating Tumor Cells and Microsatellite Instability Status in Predicting Outcome of Advanced CRC Patients.
Messaritakis I; Sfakianaki M; Vogiatzoglou K; Koulouridi A; Koutoulaki C; Mavroudis D; Tzardi M; Gouvas N; Tsiaoussis J; Souglakos J
J Pers Med; 2020 Nov; 10(4):. PubMed ID: 33217974
[TBL] [Abstract][Full Text] [Related]
35. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
Peeters M; Price TJ; Cervantes A; Sobrero AF; Ducreux M; Hotko Y; André T; Chan E; Lordick F; Punt CJ; Strickland AH; Wilson G; Ciuleanu TE; Roman L; Van Cutsem E; Tzekova V; Collins S; Oliner KS; Rong A; Gansert J
J Clin Oncol; 2010 Nov; 28(31):4706-13. PubMed ID: 20921462
[TBL] [Abstract][Full Text] [Related]
36. Mesenchymal marker and LGR5 expression levels in circulating tumor cells correlate with colorectal cancer prognosis.
Wang W; Wan L; Wu S; Yang J; Zhou Y; Liu F; Wu Z; Cheng Y
Cell Oncol (Dordr); 2018 Oct; 41(5):495-504. PubMed ID: 29949050
[TBL] [Abstract][Full Text] [Related]
37. Detection of KRAS Exon 2 Mutations in Circulating Tumor Cells Isolated by the ISET System from Patients with RAS Wild Type Metastatic Colorectal Cancer.
Matikas A; Voutsina A; Lagoudaki E; Hatzidaki D; Trypaki M; Stoupis G; Tzardi M; Mavroudis D; Georgoulias V
Transl Oncol; 2017 Aug; 10(4):693-698. PubMed ID: 28692881
[TBL] [Abstract][Full Text] [Related]
38. The prognostic role of disseminated tumor cells detected in peripheral blood and bone marrow of colorectal cancer.
Wu P; Tang RN; Zou JH; Wang FC
Hepatogastroenterology; 2012 Oct; 59(119):2164-7. PubMed ID: 23178553
[TBL] [Abstract][Full Text] [Related]
39. KRAS mutations by digital PCR in circulating tumor cells isolated from the mesenteric vein are associated with residual disease and overall survival in resected colorectal cancer patients.
Li Y; Monzo M; Moreno I; Martinez-Rodenas F; Hernandez R; Castellano JJ; Canals J; Han B; Muñoz C; Navarro A
Int J Colorectal Dis; 2020 May; 35(5):805-813. PubMed ID: 32088737
[TBL] [Abstract][Full Text] [Related]
40. Use of Liquid Biopsy in Monitoring Colorectal Cancer Progression Shows Strong Clinical Correlation.
Sun Q; Liu Y; Liu B; Liu Y
Am J Med Sci; 2018 Mar; 355(3):220-227. PubMed ID: 29549923
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
